News

The agreement between Bristol Myers Squibb and Dragonfly Therapeutics includes DF6002, an extended half-life IL12 cytokine, which is being studied as a treatment for advanced solid tumours in

In October 2018, the companies first announced their collaboration for the discovery, development and commercialisation of advanced targeted immuno-oncology treatments for cancer. As part of the expanded multi-year

ASC22(Envafolimab) Phase IIa clinical trial is a single dose escalation study with three subcutaneously administered doses (0.3, 1.0 and 2.5 mg/kg) to explore the safety and efficacy of

Licensed from the Oxford University, the AZD1222 vaccine candidate had delivered strong immune responses against the Covid-19 causing SARS-CoV-2 virus in all participants in a phase I/II trial

As per terms of the deal, Sanofi will purchase all of the outstanding shares of Principia by paying $100 per share in cash. Principia Biopharma is engaged in

Niclosamide was recently identified by Institut Pasteur Korea as a potent inhibitor of SARS-CoV-2, the virus causing COVID-191. For a number of years, UNION has worked with niclosamide

The acceptance of IND will allow Enzychem to assess EC-18 in a phase 2 clinical study in patients with ARDS due to Covid-19. The EC-18 is originally obtained

Started in May 2020, BLADE-CONQUER (ClinicalTrials.gov NCT04334460) is a double-blind, placebo-controlled clinical trial assessing the efficacy and safety of BLD-2660 on lung function and recovery time in hospitalized

Childhood ILD (chILD) includes more than 200 rare respiratory disorders that can affect infants, children and adolescents, making it difficult for them to breathe. In some cases, fibrosis